TL;DR
Findings prove that SYVN1 could promote the malignant characteristics of A549 cells by modulating the GATA3/NRP1 axis and that targeting SYVN1 could represent a promising therapeutic approach for treating lung cancer.
Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in non-small cell lung cancer (NSCLC) and is associated with aggressive tumor behavior and poor patient prognosis. However, the molecular mechanisms through which EZH2 drives NSCLC progression, particularly its interplay with major oncogenic signaling casca...
These findings establish RNF126 as a critical contributor to cisplatin resistance in ovarian cancer via regulation of the Numb/Notch1 pathway and highlight its potential as a therapeutic target to counteract chemoresistance.
HIST1H4L was significantly upregulated in SCLC tumors versus normal tissues and enriched in DNA transcription-related pathways and correlated with poor patient survival; critically, high HIST1H4L expression correlated with poor patient survival.
A potential mechanism by which HOXC9 contributes to ESCC progression via AKT/mTOR-mediated inhibition of mitochondria-dependent apoptosis and promotion of cell proliferation is identified.
It is identified that MAGI3, as a suppressor in NSCLC progression, repressed the Wnt pathway‑including TAZ degradation, impaired β‑catenin nuclear translocation, and diminished TCF/LEF transcription‑thereby restraining tumorigenesis and metastasis of NSCLC.
KIAA1429 knockdown may suppress OS progression by inhibiting m6A-dependent SLC7A11 expression, thereby promoting ferroptosis and targeting the KIAA1429/SLC7A11 axis may represent a promising therapeutic strategy for OS.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
